<--- Back to Details
First PageDocument Content
Biology / Pharmacology / Otologicals / Tuberculosis / Pharmaceuticals policy / Neomycin / Aminoglycoside / Kanamycin / Streptomycin / Aminoglycoside antibiotics / Medicine / Microbiology
Date: 2013-07-21 05:42:25
Biology
Pharmacology
Otologicals
Tuberculosis
Pharmaceuticals policy
Neomycin
Aminoglycoside
Kanamycin
Streptomycin
Aminoglycoside antibiotics
Medicine
Microbiology

Microsoft Word - Antibiotic resistance marker gene npII

Add to Reading List

Source URL: www.ema.europa.eu

Download Document from Source Website

File Size: 46,00 KB

Share Document on Facebook

Similar Documents

FINECURE PHARMACEUTICALS LIMITED NOMINATION AND REMUNERATION POLICY I. PREAMBLE

DocID: 1vhvU - View Document

For over 20 years, Health Policy Associates has been providing practical and highly efficient consulting solutions to companies involved in developing new medical device technologies, pharmaceuticals and biologics. Clin

DocID: 1vdpM - View Document

FINECURE PHARMACEUTICALS LIMITED POLICY ON ARCHIVAL OF DOCUMENTS 1. PREAMBLE The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR") came into force fr

DocID: 1v1UD - View Document

FINECURE PHARMACEUTICALS LTD. CIN: U24230GJ2005PLC045724 CORPORATE SOCIAL RESPONSIBILITY POLICY Registered Office:

DocID: 1uqeg - View Document

Privacy Policy Revised as of April 4, 2018 Welcome to www.minivelle.com, a web site owned by Noven Pharmaceuticals, Inc. (Noven, our, or we). This Privacy Policy is designed to tell you about our practices regarding coll

DocID: 1un1u - View Document